# Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer

> **NCT00612586** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 117 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Enzastaurin
- **DRUG:** Placebo
- **DRUG:** Leucovorin (LV)
- **DRUG:** 5-fluorouracil (5-FU)
- **DRUG:** Bevacizumab (Bev)

## Key facts

- **NCT ID:** NCT00612586
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-01
- **Final completion:** 2011-11
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2020-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00612586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00612586, "Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00612586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*